Amyvid Training Issues Lead To Complete Response Letter, Could Force More Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says consistent training program needed for market implementation of amyloid diagnostic. Lilly says issues will be resolved promptly.
You may also be interested in...
Lilly Gains Amyvid Approval, But Reimbursement Still A Hurdle
Lilly’s Avid has gained approval for its imaging agent Amyvid, a new tool in the Alzheimer’s disease diagnosis arsenal.
FDA Relaxes Safety Requirements For Alzheimer's Trials, But Uncertainty Persists
Sponsors and contract research organizations expressed cautious optimism about FDA's adoption of some of the recommendations of the Alzheimer's Association Research Roundtable Workgroup, but the agency isn't specifying which recommendations it is accepting.